NovoCure Ltd. (NVCR) PT Raised to $99 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts NVCR Hot Sheet
Price: $14.45 +0.35%
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
JPMorgan analyst Jessica Fye raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $99.00 (from $86.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- Innio NV (INIO) PT Lowered to $35 at BNP Paribas Exane
- Sandfire Resources NL (SFR:AU) (SNDFY) PT Lowered to AUD25 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
